Clinical trials: Peritoneal Malignancy
Peritoneal Carcinomatosis
Treating Peritoneal Carcinomatosis With PIPAC
This is a feasibility study that aims to evaluate whether PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) is a safe and feasible treatment in Danish patients with peritoneal cancer.
- Trial name
- NCT02320448
- Testing
- PIPAC
- Where
- Denmark
- Volunteers
- 35 people
- Sponsor
- Michael Bau Mortensen
Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer
Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer
The overall objective of this study is to assess turnaround time, pre-BRCA test onco-genetic counselling quality and satisfaction with a new onco-genetic BRCA testing model.
- Trial name
- ENGAGE (NCT02406235)
- Where
- 26 sites in United States, Italy and 1 more
- Volunteers
- 710 people
- Sponsor
- AstraZeneca
Peritoneal Carcinomatosis
Register Study of Patients With Peritoneal Carcinomatosis Treated With PIPAC (Pressurized Intra-peritoneal Aerosol-Chemotherapy)
The study will follow up patients with peritoneal carcinomatosis from colorectal, ovarian, gastric, pancreatic cancers and primary peritoneal tumors and undergoing a diagnostic laparoscopy / laparotomy, a PIPAC as single dose or…
- Trial name
- PIPAC_01 (NCT03100708)
- Testing
- PIPAC
- Where
- Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Leipzig
Appendix Carcinoma, Carcinomatosis
Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy
This study learns if depression, anxiety, and catastrophizing (thought patterns that prompt people to expect the worst) are associated with chronic pain after surgery among patients who are scheduled to have cytoreductive surgery…
- Conditions
- Appendix Carcinoma, Carcinomatosis, Colorectal Carcinoma, Gastric Carcinoma
- Trial name
- NCT05083338
- Testing
- Biospecimen Collection, Pain Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Peritoneal Carcinomatosis
Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
This prospective multicenter interventional pre-post study aims to evaluate the effect of implementing an Enhanced Recovery After Surgery (ERAS) protocol in patients with peritoneal carcinomatosis undergoing cytoreductive surgery…
- Trial name
- EPICH (NCT07493876)
- Testing
- ERAS Perioperative Management Protocol
- Where
- 2 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Colorectal Cancer
A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
Colorectal cancer may be caused by a build-up of genetic defects, or damaged genes within the body's cells. When genes are damaged, the body may be unable to produce a group of proteins, called cytokines, used by the immune…
- Trial name
- NCT01300858
- Testing
- EGEN-001-301
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- EGEN, Inc.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
This is a Phase I trial to determine the maximum tolerated dose/maximum feasible dose (MTD/MFD) of a single infusion of FATE-NK100 via intra-peritoneal catheter in women with recurrent ovarian, fallopian tube or primary…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03213964
- Testing
- FATE-NK100, Interleukin-2
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Oligometastatic Gastric Adenocarcinoma
PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer
Peritoneal Carcinomatosis is the most frequent site of metastases observed in patients with gastric cancer. Current standard treatment for these patients is palliative systemic chemotherapy, but the prognosis is very poor.
- Trial name
- PIPAC_VEROne (NCT05303714)
- Testing
- FOLFOX and PIPAC
- Where
- Italy
- Volunteers
- 98 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Ovarian Cancer
Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
Randomized phase 3 trial evaluating niraparib plus dostarlimab vs chemotherapy at physician's choice in the treatment of recurrent ovarian, fallopian tube or primary peritoneal cancer patients for which platinum is not an option
- Trial name
- NItCHE-MITO33 (NCT04679064)
- Testing
- Niraparib, Dostarlimab, Pegylated liposomal doxorubicin
- Where
- 8 sites in Italy
- Volunteers
- 427 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Colorectal Cancer Control and Prevention, Colorectal Cancer
Prophylactic PIPAC in Patients With High-risk Colorectal Cancer
In a multicentric randomized controlled trial, we will compare standard surgery (consisting in removal of the primary cancer) followed by 6 months of adjuvant chemotherapy associated with 3 cycles of oxaliplatin-based PIPAC (4-6…
- Conditions
- Colorectal Cancer Control and Prevention, Colorectal Cancer, Colorectal Cancer Stage II, Colorectal Cancer Stage III
- Trial name
- PROPAC (NCT06839092)
- Testing
- oxaliplatin-based PIPAC, Control (Standard treatment)
- Volunteers
- 160 people
- Sponsor
- Jeremy Meyer
Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, Platinum Sensitve Relapse
Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum
Patients with epithelial ovarian cancer, fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinum/taxane containing chemotherapy have a significant chance of entering complete clinical remission but…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, Platinum Sensitve Relapse, Anemia
- Trial name
- NCT00189371
- Testing
- paclitaxel, carboplatin, epoetin alpha
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- AGO Study Group
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
This randomized clinical trial is studying the side effects of oregovomab and to see how well it works with or without cyclophosphamide in treating patients with stage III or stage IV ovarian epithelial cancer, fallopian tube…
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage III Ovarian Cancer
- Trial name
- NCT00551265
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Oregovomab
- Where
- United States
- Sponsor
- Gynecologic Oncology Group
Digestive Cancer
Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers
Current curative treatment of digestive peritoneal carcinomatosis consists of complete cytoreduction surgery associated with intraperitoneal chemotherapy.
- Trial name
- PIPOX (NCT03294252)
- Testing
- 5-Fluorouracil, L-Folinic acid, Oxaliplatin
- Where
- 3 sites in France
- Volunteers
- 34 people
- Sponsor
- Institut Cancerologie de l'Ouest
Ovarian Cancer, Fallopian Tube Cancer
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma
- Trial name
- N-Plus (NCT05460000)
- Testing
- 3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy
- Where
- 50 sites in Austria, Belgium and 4 more
- Volunteers
- 640 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Ovarian Neoplasm
DOXIL for Consolidation Therapy in Ovarian Cancer.
The primary objective for this study is to evaluate the development, frequency and severity of hand foot syndrome (HFS) in ovarian cancer subjects treated with Doxil®, as consolidation therapy, on an every two week schedule.
- Trial name
- NCT00248248
- Testing
- liposomal doxorubicin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Southeastern Gynecologic Oncology
Ovarian Carcinoma
MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
The purpose of this study is to evaluate the anti-tumour activity of alisertib (MLN8237) in the treatment of participants with platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal…
- Trial name
- NCT00853307
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab
This phase II trial studies how well computed tomography perfusion imaging works in predicting outcomes in patients with ovarian, fallopian tube, or primary peritoneal cancer who are receiving bevacizumab.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03412630
- Testing
- Computed Tomography Perfusion Imaging
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Ovarian Cancer, Ovarian Neoplasms
EDMONd - Elemental Diet in Bowel Obstruction
A feasibility study to provide 'proof of concept' of Elemental Diet (ED) as an acceptable/ useful feeding option for patient with inoperable malignant bowel obstruction and to examine the impact of ED on quality of life
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Disease, Peritoneal Neoplasms
- Trial name
- EDMONd (NCT03150992)
- Testing
- Elemental 028 Extra Liquid
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Fallopian Tube Cancer, Ovarian Cancer
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00702299
- Testing
- cisplatin, paclitaxel, pemetrexed disodium
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Arizona
Peritoneal Cancer
Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
The purpose of this study is to assess the dynamics of inflammatory parameters in presence or absence of infectious complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
- Trial name
- NCT02741167
- Testing
- CRS and HIPEC
- Where
- Switzerland
- Volunteers
- 90 people
- Sponsor
- University of Zurich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.